Concentrated solution of stabilised ozone for treatment of inflammatory processes

FIELD: medicine.

SUBSTANCE: concentrated solution of stabilized ozone for treatment of inflammatory processes contains the ozone carrier, which includes the isotonic saline and ozone, and in addition, perfluorocarbon or mixture of perfluorocarbons and the surfactant. The components are taken in particular amount.

EFFECT: concentrated solution of stabilized ozone has long-lasting antimicrobial activity and storage time.

6 ex, 2 dwg

 

The invention relates to medicine and can be used for the treatment of inflammatory processes.

It is known that ozone is widely used in medicine [Miroshin S.I., Semenov S.V. Sanitation of the abdominal cavity in diffuse peritonitis using ozone // Nizhny Novgorod medical journal. - 1996. No. 2. - P.46-48]. In dentistry the use of blowing ozone is contraindicated, as the majority of the lesions found in the mouth. So in dentistry instead of gaseous ozone is widely used ozone solutions in isotonic saline solution and distilled water.

However, these drugs are unstable and should be used within a few minutes after saturation with ozone, which causes great inconvenience to use [Yanbaev A.K., Miroshin SR, Peretyagin S. p. Application of ozone in the treatment of wounds of the eye in combat // Nizhny Novgorod medical journal. - 1996. No. 1. - P.57-58].

A method of obtaining the product obtained by the ozonization of triglycerides of fatty acids, in particular olive oil. The effectiveness of this drug due to its ozonides of unsaturated fatty acids. However, when used in medicine emulsion of ozonides of olive oil, such important biological effects of drugs of ozone as a bactericidal action, and then the stimulation of tissue regeneration in the recommended concentrations are negligible. At the same time, at high concentrations of ozonides olive oil manifest their adverse side effects - damage to tissues and inhibition of regeneration [Sorokin S.R., Kontorshikova PHD, Petrikas A.Z. Influence of ozonized solutions used in dental practice, acid microflora of the oral cavity // Nizhny Novgorod medical journal. - 1997. No. 2. - P.66-67].

The closest to the proposed product containing ozone is a solution of ozone in isotonic saline solution with ozone concentration from 1 to 20 mg/l (0,0001-0,002%) [Yanbaev A.N., The Miroshin SR, Peretyagin S. p. Application of ozone in the treatment of wounds of the eye in combat // Nizhny Novgorod medical journal. - 1996. No. 1. - P.57-58].

The technical result of the present invention is to increase the shelf life of the drug containing ozone.

The technical result is achieved by the fact that the drug is stable ozone containing ozone media, including isotonic saline solution and ozone, the distinguishing feature is that the carrier of ozone contains perfluorocarbons, or a mixture of perfluorocarbons and surfactant in the following ratio of components (wt.%):

the perfluorocarbons, or a mixture of perfluorocarbons1-90
surfactant0,01-50
ozone0,0001-0,03
isotonic salinerest

The offered product has a high temporal stability and ability to achieve high concentrations of ozone.

It is shown that in mixtures of perfluorocarbons, surfactants and isotonic salt solution, in particular produced by domestic medical industry entitled "Perftoran", the solubility of ozone in tens times higher than in isotonic saline or water. Also significantly higher temporal stability of ozone dissolved in such mixtures, in comparison with solutions of ozone in water and isotonic saline: ozone concentration in the emulsions of perfluorocarbons is reduced by half after 5-7 days, and not after 3-5 minutes in water and isotonic saline solution. So ozonated emulsions of perfluorocarbons, in particular ozonated "Perftoran", can be used for medical purposes for 5-7 days after cooking.

The proposed composition possesses antimicrobial properties, continuing until the ozone concentration of 1.6 mg/l (0,00016%).

Example 1.

Ozonation mixture of performanceline (16 wt%), surface-active substances is and proxanol is chosen (to 0.05 wt.%) and isotonic saline (83,95 wt.%). The mixture is brought to a homogeneous emulsion by mechanical shaking.

Ozonation of the test solution in this, as in the other examples, is carried out using an industrial apparatus for ozone company "Madison".

Exiting the apparatus of ozone-oxygen mixture is passed over the surface saniruemogo liquid poured on the bottom of the bottle for injection solutions with a volume of 500 ml rubber stopper insert 2 metal needle for extraction of plasma (sealed with a sharp end and a perforation in the walls around the end). One of these needles silicone tube connected with the outlet pipe of the ozonizer. It should reach almost to the bottom of the bottle. Second, reaching only to the middle of the bottle, connected to the suction pipe system neutralization of ozone the same instrument.

Ozone is not absorbed by the fluid being sucked back into the same apparatus in order to neutralize the remaining ozone.

Volume saniruemogo liquid - 50,0 ml feed Rate of oxygen 0.35 l/min, the concentration of ozone in the effluent from the apparatus ozonized oxygen 70 mg/l, time of ozonation 15 minutes the Temperature of the solution 23°C.

The ozone concentration in the solution is determined by iodometric method.

The sample solution from 1 to 10.0 ml (depending on the concentration of ozone) add 1.0 ml of 10% solution of potassium iodide, 1.0 ml 3-5% solution with what Laney acid and 1-2 drops of 1% starch solution. After 10 minutes the sample is titrated 0.05 to 0.1 N. the solution of thiosulfate with exactly a particular title to bleaching of starch. The volume of the sample and the concentration of the solution of thiosulfate are chosen so that the volume of thiosulfate solution, followed by titration of the sample, can be measured with an accuracy of not less than 5%.

Calculation:

The ozone concentration, mg/l

where:

where Vs is the volume of sample, ml (or weight of sample, g);

Vt is the volume of sodium thiosulfate solution, followed by titration, ml;

2400 is the number of micrograms of ozone corresponding to 1 ml of 0.1 n thiosulfate solution;

It is the ratio of the titer used solution of thiosulfate to the title exactly 0.1 G. of a solution of thiosulfate.

The ozone concentration in the emulsion after ozonation is the results of three measurements (M±σ):

K=1,002; Vs=2.0 ml; Vt=0,202±0,035 ml.

X=243±42 mg/l (0,0243±0,0042 wt.%)

Example 2.

Ozonation of the drug "Perftoran" and the determination of ozone concentration were carried out as described in example 1.

The resulting preparation is stable ozone is divided into 2 portions by 25.0 ml, which is maintained at a temperature of +4°and at -20°C.

The results of determining the concentration of ozone in the ozonated product within 14 days to determine the stability of ozone is shown in figure 1.

Example 3 (comparative).

Ozonation isotonic saline is astora and determining the concentration of ozone is carried out, as described in example 1. The liquid temperature of 23°C.

Immediately after ozonation isotonic saline concentration of ozone in it was by the results of three measurements (M±σ): 6,5±1.0 mg/L.

The results of determination of ozone concentration over different periods of time after ozone is shown in figure 2.

Example 4.

Determination of antimicrobial activity of a solution of ozone in medicine "Perftoran" hold across the width of the zone of lysis of a culture of E. coli LE 392 on the surface of agar concentration of ozone.

Volume saniruemogo emulsion - 50,0 ml feed Rate of oxygen 0.35 l/min, ozone concentration of 70 mg/l, time of ozonation 15 min. Temperature of 21°C.

The ozone concentration in the solution is determined by iodometric method.

Detail the method of ozonation and determine the concentration of ozone is described in example 1.

After 20 min after ozonation in the emulsion determine the ozone concentration. The emulsion is diluted newtonianism drug "Perftoran" to obtain different concentrations of ozone and used in the test for antimicrobial activity across the width of the zone of lysis of a culture of E. coli LE 392 on the surface of the agar.

The test solution are inserted in holes on the surface of the agar, seeded with a lawn of the daily culture of the test microorganism.

Incubation carried out for 24 h at 37°C.

Results the ATA is shown in figure 3.

As can be seen from comparing the data shown in figure 1 and 2, the concentration of ozone in the ozonated "Perftoran" tens of times higher than the concentration of ozone in the ozonated isotonic saline solution. The concentration of ozone in the ozonated isotonic saline is decreased by half after 8 minutes In ozonated "Perftoran" reducing ozone concentrations occurred only twice in 5 days.

Thus, the stability of ozone in a mixture of perfluorocarbons, a surfactant and an isotonic saline hundreds of times higher than in isotonic saline solution.

As follows from these data, shown in figure 3, the antimicrobial activity of the drug is stable ozone is retained until the ozone concentration of 1.6 mg/l (0,00016 wt.%).

Example 5.

Ozonation of a mixture containing 5.0 g of perftoran (20% mixture of perfluorocarbons); 50.0 g of surface-active substances proxanol is chosen 268; 45,0 g bidistilled water. The mixture is produced by the sequential mixing of the components in the specified order with constant stirring to obtain a homogeneous emulsion.

Ozonation of the resulting emulsion, containing by weight 1% perfluorinated hydrocarbons and 50% surfactant, and the concentration of ozone is carried out as described in example 1. The temperature of the liquid 22°C. the Concentration of ozone by the results of three parallel is the preliminary measurements immediately after ozonation is 18,2± 3.7 mg/l Ozonated mixture maintained at +4°C for 5 days (7500 rpm). Ozone concentration according to the results of three parallel measurements after storage is 5.4±2,9 mg/l (30% of the original).

Example 6.

Ozonation mixture containing performanceline 90 g, surface-active substances proxanol is chosen - 0,01 g bidistilled water - 9,99, the Mixture is produced by the sequential mixing of the components in the specified order with constant stirring to obtain a homogeneous emulsion.

Ozonation of the resulting emulsion, containing by weight 90% perfluorinated hydrocarbons and 0.01% surfactant, and the concentration of ozone is carried out as described in example 1. The temperature of the liquid 22°C. the Concentration of ozone by the results of three parallel measurements immediately after ozonation is 288±21 mg/l Ozonated mixture maintained at +4°C for 5 days (7500 rpm). Ozone concentration according to the results of three parallel measurements after storage 108±14 mg/l (44% of the original).

As shown in examples 5 and 6, the stability and concentration of ozone in the mixture increase with increasing concentration of the perfluorocarbon.

A concentrated solution of stabilized ozone for the treatment of inflammatory processes that contain ozone, including isotonic saline solution and ozone, characterized in that the carrier ozone further comprises a perfluorocarbons, or a mixture of perfluorocarbons and surfactant in the following ratio of components, wt.%:

the perfluorocarbons, or a mixture of perfluorocarbonsof 1.0 to 90.0
surfactantfrom 0.01 to 50.0
ozone0,0001-0,03
isotonic salinerest



 

Same patents:

FIELD: medicine.

SUBSTANCE: bioactive food additive contains the products of Morinda citrifolia processing, which is used to inhibit the aromatase or aromatase enzymes transforming the androgens to estrogens, to inhibit the receptor binding to estrogens and to decrease and/or regulate the estrogen production. The invention reduces and regulates the estrogen production.

EFFECT: efficient in treatment of estrogen-dependent cancer and conversion of estrogen-dependent malignant tumors.

60 cl, 1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: strain of Tramertes pubescens VKPM Р-839 is characterised by increased ergosterine synthesis. The ergosterine content in biomass is 0.25 g/100 g. The medicine is made of dried and purified biomass of strain of Tramertes pubescens VKPM Р-839, which contains total protein 45 weight%, carbohydrates 27 weight%, lipids 4.5 weight%, nucleic acids 4 weight%, mineral substances 7 weight%), vitamins 0.4 weight%,).

EFFECT: medicine stimulates the immunogenesis and promotes the liver functional recovery.

2 cl, 12 tbl, 4 ex

Compound // 2323940

FIELD: chemistry.

SUBSTANCE: photosensitising agents obtained by reducing a double bond in porphyrinic macrocycle of sulphonated mesotetraphenylporphyrine, preferably disulphonated mesotetraphenylporphyrine, such as TPPS2a. Resulting sulphonated mesotetraphenylchlorines are compounds of formula (I) , (where X stands for -SO3Н; each of n, p, q and r independently stands for 0 or 1; and sum of n, p, q and r is an integer from 1 to 4, preferably at least 2, in particular, 2 or 4), isomers or isomeric mixture. Compounds in accordance with the said invention and pharmaceutically suitable salts thereof have a high extinction coefficient in the region of 630 to 680 nm.

EFFECT: compounds are widely used as photosensitising agents for photochemical internalisation of molecules and photodynamic therapy.

25 cl, 8 ex, 8 dwg

FIELD: CHEMISTRY.

SUBSTANCE: crushed plant raw material with addition of ethanol modifier is extracted in two stages. At the first stage, supercritical carbon dioxide is used, which results in carbon dioxide extract further dissolved in ethanol by bubbling the extraction agent at atmospheric pressure. At the second stage, solvent cake is extracted with ethanol solution, which results in ethanolic extract.

EFFECT: invention increases grade of extraction of biologically active substances.

2 ex

FIELD: medicine; pharmacology.

SUBSTANCE: medicine for treatment of tuberculosis, contains the 30% alcoholic tincture of medicinal plants: knotgrass (Polygonum aviculare) herb, garden violet (Viola tricolor) herb, aspen (populus tremula) rind, agrimony (Agrimonia) herb, agrimony (Agrimonia) roots, rough-fruited cinquefoil (Potentilla recta) herb, golden thoroughwax (Bupleurum) herb, medic hop (Medicago lupulina) cone, Adonis vernalis herb, late red bartsia (Odontites vulgaris) herb, Betula leaf, bird cherry (Prunus padus) tree rind, common peony (Paeonia officinalis) root, common burdock (Arctium lappa) roots, foxtail clover (Trifolium rubens) bloom, cowberry (Comarum palustre) roots, Inula root, wheat grass (Agropyron) root, garden angelica (Angelica officinalis) root, coltsfoot herb, snowdrop anemone (Anemone sylvestris) herb, snowdrop anemone (Anemone sylvestris) root, locoweed semilunar (Astragalus) herb, arborescent aloe (Arborescence aloe) succus, swallowwort (Chelidonium majus) herb, black current (Ribes nigrum) leaf, garlic (Allium sativum) bulb, greater burnet (Sanguisorba officinalis) root, lady's finger (Lathyrus pratensis) herb, dandelion (Taraxacum officinale) root, stringing nettle (Urtica dioica) herb, common origanum (Origanum vulgare) herb, ginger plant (Tanacetum vulgare) herb, bottle brush (Equisetum arvense) herb, common wormwood (Artemisia absinthium) herb, crystal tea ledum (Ledum palustre) herb, common juniper (Juniperus communis) needle, parnassia herb, mother-of-thyme herb, flat-leaved snakeroot (Eryngium) herb, shinleaf (Ramischia secunda) herb, willow herb root and field pennycress (Thlaspi arvense) herb taken in specific proportion and added by 3 volume percent of 10% propolis tincture.

EFFECT: tincture shows efficiency in treating tuberculosis.

3 tbl

FIELD: medicine; pharmacology.

SUBSTANCE: medicine for treatment of tuberculosis, contains the 30% alcoholic tincture of medicinal plants: knotgrass (Polygonum aviculare) herb, garden violet (Viola tricolor) herb, aspen (populus tremula) rind, agrimony (Agrimonia) herb, agrimony (Agrimonia) roots, rough-fruited cinquefoil (Potentilla recta) herb, golden thoroughwax (Bupleurum) herb, medic hop (Medicago lupulina) cone, Adonis vernalis herb, late red bartsia (Odontites vulgaris) herb, Betula leaf, bird cherry (Prunus padus) tree rind, common peony (Paeonia officinalis) root, common burdock (Arctium lappa) roots, foxtail clover (Trifolium rubens) bloom, cowberry (Comarum palustre) roots, Inula root, wheat grass (Agropyron) root, garden angelica (Angelica officinalis) root, coltsfoot herb, snowdrop anemone (Anemone sylvestris) herb, snowdrop anemone (Anemone sylvestris) root, locoweed semilunar (Astragalus) herb, arborescent aloe (Arborescence aloe) succus, swallowwort (Chelidonium majus) herb, black current (Ribes nigrum) leaf, garlic (Allium sativum) bulb, greater burnet (Sanguisorba officinalis) root, lady's finger (Lathyrus pratensis) herb, dandelion (Taraxacum officinale) root, stringing nettle (Urtica dioica) herb, common origanum (Origanum vulgare) herb, ginger plant (Tanacetum vulgare) herb, bottle brush (Equisetum arvense) herb, common wormwood (Artemisia absinthium) herb, crystal tea ledum (Ledum palustre) herb, common juniper (Juniperus communis) needle, parnassia herb, mother-of-thyme herb, flat-leaved snakeroot (Eryngium) herb, shinleaf (Ramischia secunda) herb, willow herb root and field pennycress (Thlaspi arvense) herb taken in specific proportion and added by 3 volume percent of 10% propolis tincture.

EFFECT: tincture shows efficiency in treating tuberculosis.

3 tbl

FIELD: medicine; pharmacology.

SUBSTANCE: medicine for treatment of tuberculosis, contains the 30% alcoholic tincture of medicinal plants: knotgrass (Polygonum aviculare) herb, garden violet (Viola tricolor) herb, aspen (populus tremula) rind, agrimony (Agrimonia) herb, agrimony (Agrimonia) roots, rough-fruited cinquefoil (Potentilla recta) herb, golden thoroughwax (Bupleurum) herb, medic hop (Medicago lupulina) cone, Adonis vernalis herb, late red bartsia (Odontites vulgaris) herb, Betula leaf, bird cherry (Prunus padus) tree rind, common peony (Paeonia officinalis) root, common burdock (Arctium lappa) roots, foxtail clover (Trifolium rubens) bloom, cowberry (Comarum palustre) roots, Inula root, wheat grass (Agropyron) root, garden angelica (Angelica officinalis) root, coltsfoot herb, snowdrop anemone (Anemone sylvestris) herb, snowdrop anemone (Anemone sylvestris) root, locoweed semilunar (Astragalus) herb, arborescent aloe (Arborescence aloe) succus, swallowwort (Chelidonium majus) herb, black current (Ribes nigrum) leaf, garlic (Allium sativum) bulb, greater burnet (Sanguisorba officinalis) root, lady's finger (Lathyrus pratensis) herb, dandelion (Taraxacum officinale) root, stringing nettle (Urtica dioica) herb, common origanum (Origanum vulgare) herb, ginger plant (Tanacetum vulgare) herb, bottle brush (Equisetum arvense) herb, common wormwood (Artemisia absinthium) herb, crystal tea ledum (Ledum palustre) herb, common juniper (Juniperus communis) needle, parnassia herb, mother-of-thyme herb, flat-leaved snakeroot (Eryngium) herb, shinleaf (Ramischia secunda) herb, willow herb root and field pennycress (Thlaspi arvense) herb taken in specific proportion and added by 3 volume percent of 10% propolis tincture.

EFFECT: tincture shows efficiency in treating tuberculosis.

3 tbl

FIELD: medicine; pharmacology.

SUBSTANCE: medicine for treatment of tuberculosis, contains the 30% alcoholic tincture of medicinal plants: knotgrass (Polygonum aviculare) herb, garden violet (Viola tricolor) herb, aspen (populus tremula) rind, agrimony (Agrimonia) herb, agrimony (Agrimonia) roots, rough-fruited cinquefoil (Potentilla recta) herb, golden thoroughwax (Bupleurum) herb, medic hop (Medicago lupulina) cone, Adonis vernalis herb, late red bartsia (Odontites vulgaris) herb, Betula leaf, bird cherry (Prunus padus) tree rind, common peony (Paeonia officinalis) root, common burdock (Arctium lappa) roots, foxtail clover (Trifolium rubens) bloom, cowberry (Comarum palustre) roots, Inula root, wheat grass (Agropyron) root, garden angelica (Angelica officinalis) root, coltsfoot herb, snowdrop anemone (Anemone sylvestris) herb, snowdrop anemone (Anemone sylvestris) root, locoweed semilunar (Astragalus) herb, arborescent aloe (Arborescence aloe) succus, swallowwort (Chelidonium majus) herb, black current (Ribes nigrum) leaf, garlic (Allium sativum) bulb, greater burnet (Sanguisorba officinalis) root, lady's finger (Lathyrus pratensis) herb, dandelion (Taraxacum officinale) root, stringing nettle (Urtica dioica) herb, common origanum (Origanum vulgare) herb, ginger plant (Tanacetum vulgare) herb, bottle brush (Equisetum arvense) herb, common wormwood (Artemisia absinthium) herb, crystal tea ledum (Ledum palustre) herb, common juniper (Juniperus communis) needle, parnassia herb, mother-of-thyme herb, flat-leaved snakeroot (Eryngium) herb, shinleaf (Ramischia secunda) herb, willow herb root and field pennycress (Thlaspi arvense) herb taken in specific proportion and added by 3 volume percent of 10% propolis tincture.

EFFECT: tincture shows efficiency in treating tuberculosis.

3 tbl

FIELD: medicine; pharmacology.

SUBSTANCE: medicine for treatment of tuberculosis, contains the 30% alcoholic tincture of medicinal plants: knotgrass (Polygonum aviculare) herb, garden violet (Viola tricolor) herb, aspen (populus tremula) rind, agrimony (Agrimonia) herb, agrimony (Agrimonia) roots, rough-fruited cinquefoil (Potentilla recta) herb, golden thoroughwax (Bupleurum) herb, medic hop (Medicago lupulina) cone, Adonis vernalis herb, late red bartsia (Odontites vulgaris) herb, Betula leaf, bird cherry (Prunus padus) tree rind, common peony (Paeonia officinalis) root, common burdock (Arctium lappa) roots, foxtail clover (Trifolium rubens) bloom, cowberry (Comarum palustre) roots, Inula root, wheat grass (Agropyron) root, garden angelica (Angelica officinalis) root, coltsfoot herb, snowdrop anemone (Anemone sylvestris) herb, snowdrop anemone (Anemone sylvestris) root, locoweed semilunar (Astragalus) herb, arborescent aloe (Arborescence aloe) succus, swallowwort (Chelidonium majus) herb, black current (Ribes nigrum) leaf, garlic (Allium sativum) bulb, greater burnet (Sanguisorba officinalis) root, lady's finger (Lathyrus pratensis) herb, dandelion (Taraxacum officinale) root, stringing nettle (Urtica dioica) herb, common origanum (Origanum vulgare) herb, ginger plant (Tanacetum vulgare) herb, bottle brush (Equisetum arvense) herb, common wormwood (Artemisia absinthium) herb, crystal tea ledum (Ledum palustre) herb, common juniper (Juniperus communis) needle, parnassia herb, mother-of-thyme herb, flat-leaved snakeroot (Eryngium) herb, shinleaf (Ramischia secunda) herb, willow herb root and field pennycress (Thlaspi arvense) herb taken in specific proportion and added by 3 volume percent of 10% propolis tincture.

EFFECT: tincture shows efficiency in treating tuberculosis.

3 tbl

FIELD: medicine; pharmacology.

SUBSTANCE: medicine for treatment of tuberculosis, contains the 30% alcoholic tincture of medicinal plants: knotgrass (Polygonum aviculare) herb, garden violet (Viola tricolor) herb, aspen (populus tremula) rind, agrimony (Agrimonia) herb, agrimony (Agrimonia) roots, rough-fruited cinquefoil (Potentilla recta) herb, golden thoroughwax (Bupleurum) herb, medic hop (Medicago lupulina) cone, Adonis vernalis herb, late red bartsia (Odontites vulgaris) herb, Betula leaf, bird cherry (Prunus padus) tree rind, common peony (Paeonia officinalis) root, common burdock (Arctium lappa) roots, foxtail clover (Trifolium rubens) bloom, cowberry (Comarum palustre) roots, Inula root, wheat grass (Agropyron) root, garden angelica (Angelica officinalis) root, coltsfoot herb, snowdrop anemone (Anemone sylvestris) herb, snowdrop anemone (Anemone sylvestris) root, locoweed semilunar (Astragalus) herb, arborescent aloe (Arborescence aloe) succus, swallowwort (Chelidonium majus) herb, black current (Ribes nigrum) leaf, garlic (Allium sativum) bulb, greater burnet (Sanguisorba officinalis) root, lady's finger (Lathyrus pratensis) herb, dandelion (Taraxacum officinale) root, stringing nettle (Urtica dioica) herb, common origanum (Origanum vulgare) herb, ginger plant (Tanacetum vulgare) herb, bottle brush (Equisetum arvense) herb, common wormwood (Artemisia absinthium) herb, crystal tea ledum (Ledum palustre) herb, common juniper (Juniperus communis) needle, parnassia herb, mother-of-thyme herb, flat-leaved snakeroot (Eryngium) herb, shinleaf (Ramischia secunda) herb, willow herb root and field pennycress (Thlaspi arvense) herb taken in specific proportion and added by 3 volume percent of 10% propolis tincture.

EFFECT: tincture shows efficiency in treating tuberculosis.

3 tbl

FIELD: medicine.

SUBSTANCE: target goal is resolved by combined therapy, which consists of 2 stages: out-patient home-based treatment and in-patient treatment at sanatorium-and-spa. The second stage starts immediately after the first one is completed. At the first stage, the oxygen and the blood supplies of the central nervous system, cerebral cortex, optic tract, anterior eye segment. During the second stage at sanatorium-and-spa, the therapy proper of myopia and amblyopia is performed by use of medicamentous, physical and electrophysiological methods. Irifrin, Arutimol, Vasobral, Mydriacyl and Catachrome are used in medicamentous therapy.

EFFECT: visual acuity is improved and long-term preservation is achieved.

5 cl, 1 tbl, 4 ex

Compound // 2323940

FIELD: chemistry.

SUBSTANCE: photosensitising agents obtained by reducing a double bond in porphyrinic macrocycle of sulphonated mesotetraphenylporphyrine, preferably disulphonated mesotetraphenylporphyrine, such as TPPS2a. Resulting sulphonated mesotetraphenylchlorines are compounds of formula (I) , (where X stands for -SO3Н; each of n, p, q and r independently stands for 0 or 1; and sum of n, p, q and r is an integer from 1 to 4, preferably at least 2, in particular, 2 or 4), isomers or isomeric mixture. Compounds in accordance with the said invention and pharmaceutically suitable salts thereof have a high extinction coefficient in the region of 630 to 680 nm.

EFFECT: compounds are widely used as photosensitising agents for photochemical internalisation of molecules and photodynamic therapy.

25 cl, 8 ex, 8 dwg

Indanol derivatives // 2323937

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of general formula (I): (where R1 and R2 may be identical or different, and each is a 1,3-substituted aryl with substituents from group α; R3 stands for any of the following groups: -CO-R4, -CO-O-R4, -CO-NH-R4, -CO-CH2-N(Ra)Rb, -(CH2)m-CO-R5, -(CH2)m-R5, -CO-NH-CO-N(Ra)Rb, -CO-NH-SO2-N(Ra)Rb, -CO-NH-CO-(CH2)m-N(Ra)Rb, or -CO-NH2; R4 stands for a lower alkyl, cycloalkyl, cycloalkyl substituted with 1-3 substituent from group α, lower alkenyl, lower alkynyl, halogen-substituted lower alkyl, hydroxyl-substituted lower alkyl, lower alkoxyalkyl, lower aliphatic acyloxyalkyl or lower alkoxycarbonylalkyl; R5 stands for hydroxyl, -OR4 or -N(Ra)Rb; Rа and Rb may be identical or different, each of them stands for hydrogen, hydroxyl, lower alkoxy group, hydroxyl-substituted lower alkoxyl, hydroxyl-substituted lower alkoxyalkyl, lower alkoxy lower alkoxyalkyl, cyano lower alkyl, cyano lower alkoxyalkyl, carboxy lower alkyl, carboxy lower alkoxyalkyl, aliphatic lower alkoxycarbonyl lower alkoxyalkyl, carbamoyl lower alkyl group, carbamoyl lower alkoxyalkyl, lower aliphatic acylamino lower alkyl, lower aliphatic acylamino lower alkoxyalkyl, lower alkylsulphonylamino lower alkyl, lower alkylsulphanylamino lower alkoxyalkyl, (N-hydroxy-N-methylcarbamoyl) lower alkyl, (N-hydroxy-N-methylcarbamoyl) lower alkoxyalkyl, (N-lower alkoxy-N-methylcarbamoyl) lower alkyl, (N-lower alkoxy-14-methylcarbamoyl) lower alkoxyalkyl or R4, or both, including associated nitrogen, stand for nitrogen-containing heterocyclic group or nitrogen-containing 1-3 substituted heterocyclic group with substituents from group α; m is an integer from 1 to 6; А stands for carbonyl; В stands for straight bond; D stands for oxygen atom; Е stands for С14 alkylene; n is an integer from 1 to 3; and α group is a group of substituents, which consist of halogen atoms, lower alkyls, hydroxy lower alkyls, halogen lower alkyls, carboxy lower alkyls, lower alkoxyls, hydroxy lower alkoxyls, hydroxy lower alkoxyalkyls, lower alkoxycarbonyls, carboxyls, hydroxyls, lower aliphatic acyls, lower aliphatic acylamines, (N-hydroxy-N-methylcarbamoyl) lower alkyls, (N-lower alkoxy-N-methylcarbamoyl) lower alkyls, hydroxy lower aliphatic acylamines, amines, carbamoyls and cyano groups), or pharmacologically suitable salt thereof. Invention also relates to pharmaceutical composition and method for disease prevention and treatment.

EFFECT: preparation of novel biologically active compounds.

18 cl, 117 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of formula I or pharmaceutically suitable salt or solvate thereof, where dashed line stands for additional bond, а is a number from 0 to 2, b is a number from 0 to 2, n is 2, p is 2, r is 1, М1 stands for nitrogen, М2 stands for С(R3), X stands for either a bond or alkylene group with number of carbon atoms from 1 to 6, Y stands for -С(О)- group, Z stands for a bond, or alkylene group with number of carbon atoms from 1 to 6, or alkenylene group with number of carbon atoms from 1 to 6, or -С(O)-, -CH(CN)-, -SO2- or СН2С(O)NR4- group, R1 stands for groups, R2 stands for six-membered heteroaryl ring with one or two heteroatoms chosen independently of each other from either nitrogen atom or N-O group, other atoms of the cycle being carbon, five-membered heteroaryl ring with one, two, three or four heteroatoms chosen independently of each other from nitrogen, oxygen or sulphur, other atoms of the cycle being carbon, R32 stands for substituded quinoline group, R32 stands for substituted aryl group, heterocycloalkyl group, cycloalkyl group with number of carbon atoms from 3 to 6, alkyl group with number of carbon atoms from 1 to 6, group, where the said six-membered heteroaryl ring or the said five-membered heteroaryl ring may be R6-substituted, R12 independently of others is chosen from an alkyl group with number of carbon atoms from 1 to 6, hydroxyl group or fluorine atom, provided in case R12 stands for hydroxyl or fluorine the rest of R12 cannot be bonded to a nitrogen-bonded carbon atom, or two R12 substituents form an alkyl bridge with number of carbon atoms from 1 to 2, which bonds two non-adjaicent carbon atoms of the ring, R13 independently of the others is chosen from an alkyl group with number of carbon atoms from 1 to 6, hydroxyl group, alcoxy group with number of carbon atoms from 1 to 6, or fluorine atom, provided in case R13 stands for hydroxyl or fluorine the rest of R13 cannot be bonded to a nitrogen-bonded carbon atom, or two R13 substituents form an alkyl bridge with number of carbon atoms from 1 to 2, which bonds two non-adjacent carbon atoms of the ring. See description for meaning of the other structural elements. Invention relates also to pharmaceutical compositions, as well as to application of compounds of formula I.

EFFECT: preparation of novel biologically active substances and pharmaceutical compositions.

20 cl, 659 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of formula I or pharmaceutically suitable salt or solvate thereof, where dashed line stands for additional bond, а is a number from 0 to 2, b is a number from 0 to 2, n is 2, p is 2, r is 1, М1 stands for nitrogen, М2 stands for С(R3), X stands for either a bond or alkylene group with number of carbon atoms from 1 to 6, Y stands for -С(О)- group, Z stands for a bond, or alkylene group with number of carbon atoms from 1 to 6, or alkenylene group with number of carbon atoms from 1 to 6, or -С(O)-, -CH(CN)-, -SO2- or СН2С(O)NR4- group, R1 stands for groups, R2 stands for six-membered heteroaryl ring with one or two heteroatoms chosen independently of each other from either nitrogen atom or N-O group, other atoms of the cycle being carbon, five-membered heteroaryl ring with one, two, three or four heteroatoms chosen independently of each other from nitrogen, oxygen or sulphur, other atoms of the cycle being carbon, R32 stands for substituded quinoline group, R32 stands for substituted aryl group, heterocycloalkyl group, cycloalkyl group with number of carbon atoms from 3 to 6, alkyl group with number of carbon atoms from 1 to 6, group, where the said six-membered heteroaryl ring or the said five-membered heteroaryl ring may be R6-substituted, R12 independently of others is chosen from an alkyl group with number of carbon atoms from 1 to 6, hydroxyl group or fluorine atom, provided in case R12 stands for hydroxyl or fluorine the rest of R12 cannot be bonded to a nitrogen-bonded carbon atom, or two R12 substituents form an alkyl bridge with number of carbon atoms from 1 to 2, which bonds two non-adjaicent carbon atoms of the ring, R13 independently of the others is chosen from an alkyl group with number of carbon atoms from 1 to 6, hydroxyl group, alcoxy group with number of carbon atoms from 1 to 6, or fluorine atom, provided in case R13 stands for hydroxyl or fluorine the rest of R13 cannot be bonded to a nitrogen-bonded carbon atom, or two R13 substituents form an alkyl bridge with number of carbon atoms from 1 to 2, which bonds two non-adjacent carbon atoms of the ring. See description for meaning of the other structural elements. Invention relates also to pharmaceutical compositions, as well as to application of compounds of formula I.

EFFECT: preparation of novel biologically active substances and pharmaceutical compositions.

20 cl, 659 ex

FIELD: medicine, pharmacology.

SUBSTANCE: compound formula I is described, including the pharmaceutically acceptable salts, , where: Z presents ; Q is taken from the group that consists of: -W - presents , and the pharmaceutical composition, application of compound formula (I) for preparation of antiviral medicine.

EFFECT: proposed compounds can be helpful in treatment of HIV and AIDS.

70 cl, 2 tbl, 129 ex

FIELD: chemistry.

SUBSTANCE: invention relates to crystallic hydrate of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridine-2-one of example В1, to method for preparation thereof, to anhydrous crystalline forms of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridine-2-one of examples D1, С1, Е1, as well as to pharmaceutical composition. Technical effect - easy commercial preparation of 3-(2-cyanophenyl)-5-(2-pyridyl-1-phenyl-1,2-dihydropyridine-2-one as a homogeneous crystalline form, which is an АМРА receptor antagonist and/or kainate receptor inhibitor.

EFFECT: facilitation of dyhydropyridine preparation.

26 cl, 9 ex, 11 tbl

FIELD: medicine; pharmacology.

SUBSTANCE: description is provided for the derivative of phenylalcan or phenyloxyalcan acids, formula (I), or their pharmaceutically acceptable salt or hydrolysable ester, where: R1 and R2 independently present the H or С1-3alkyl; X presents the O or (СН2)n where n is 0.1 or 2; R3 and R4 independently present the H, С1-3alkyl, -ОСН3, CF3, allyl or halogen; X1 presents О, S, SO2, SO or СН2; one of R5 and R6 independently presents hydrogen, and another - С1-6alkyl (including the ramified alkyl and, probably, the substituted С1-6alkoxy); R7 presents a phenyl or hexamerous heterocycle taken from pyridine, and each of specified phenyl or heterocycles is substituted by phenyl (probably, substituted by one ore more С1-3alkyl, CN, halogen or CF3). The pharmaceutical composition is also described.

EFFECT: compounds can be used in treatment of cardiovascular and endocrine diseases.

13 cl, 145 ex

FIELD: medicine; pharmacology.

SUBSTANCE: description is provided for the derivative of phenylalcan or phenyloxyalcan acids, formula (I), or their pharmaceutically acceptable salt or hydrolysable ester, where: R1 and R2 independently present the H or С1-3alkyl; X presents the O or (СН2)n where n is 0.1 or 2; R3 and R4 independently present the H, С1-3alkyl, -ОСН3, CF3, allyl or halogen; X1 presents О, S, SO2, SO or СН2; one of R5 and R6 independently presents hydrogen, and another - С1-6alkyl (including the ramified alkyl and, probably, the substituted С1-6alkoxy); R7 presents a phenyl or hexamerous heterocycle taken from pyridine, and each of specified phenyl or heterocycles is substituted by phenyl (probably, substituted by one ore more С1-3alkyl, CN, halogen or CF3). The pharmaceutical composition is also described.

EFFECT: compounds can be used in treatment of cardiovascular and endocrine diseases.

13 cl, 145 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel derivatives of bis-(4-alkylaminopiridinium-1)alkanes of formula (1) where X stands for lipophilic anion from the following group: triiodide I3, iodate IO3, perchlorate ClO4; Y stands for either linear or branched alkylene group, which contains 4 to 18 carbon atoms; R stands for either linear or branched alkyl, cycloalkyl or arylalkyl group, which contains 5 to 18 carbon atoms, to methods of preparation thereof and application thereof as antibacterial and antiviral substances.

EFFECT: new substances show useful biological properties.

10 cl, 6 ex

FIELD: medicine.

SUBSTANCE: method involves carrying out hernia removal in intralaminar way. Posterior longitudinal ligament defect is covered with Tacho-Comb plate after having done disk cavity curettage. Subcutaneous fat fragment on feeding pedicle is brought to dorsal surface of radix and dural sac.

EFFECT: enhanced effectiveness of treatment; reduced risk of traumatic complications.

1 dwg

Up!